Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
Summary
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Granula as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this adaptive, randomized,double-blind,controlled trial will evaluate the efficacy and safety of Yinhu Qingwen Granula in patients hospitalized with severe CoVID-19.
Timeline
- Start
- 2021-11
- Primary completion
- 2022-12
- Completion
- 2023-04
Outcome
Outcome not reported
Stopped: “There were no eligible patients with CoVID-19 in the paticipated centers.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Yinhu Qingwen Granula | Traditional medicine (herbal / TCM) | 10 % | — |
| Subject | Yinhu Qingwen Granula | Traditional medicine (herbal / TCM) | 200 ml | — |